Acacia Pharma Group plc

Financial performance has remained strong, with revenue growing from $0.00 in Q3 2017 to $0.00 in Q4 2018. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached -$7.40M in Q4 2018, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$6.90M. Net income dropped to -$6.69M, keeping EPS at -$0.07. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.